Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEN-STEM: Dendritic Cell Immunotherapy for Glioblastoma
NCT03548571Phase 3Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Autologous tumor stem cell mRNA-transfected dendritic cells in glioblastoma (GBM), sponsored by Oslo University Hospital. Started Apr 2018; status: recruiting.
02
Drugs
Autologous tumor stem cell mRNA-transfected dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03548571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548571.